Glad to hear it, but the reason for the pulmonary problem is worth speculating about and that’s why I suggested running your hypothesis about Albuferon by the science-oriented people on this board.
If very large molecules such as fusion proteins are apt to cause more safety problems than the older-generation drugs on which they are based, it could wreak havoc with the FoB programs of various companies (not just TEVA/CoGenesys and MAXY). Regards, Dew
Market Data 
Markets 
AI
